Home » Stocks » KRYS

Krystal Biotech, Inc. (KRYS)

Stock Price: $84.27 USD 0.00 (0.00%)
Updated Mar 2, 2021 4:00 PM EST - Market open
Market Cap 1.85B
Revenue (ttm) n/a
Net Income (ttm) -32.17M
Shares Out 18.79M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $84.27
Previous Close $84.27
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 81.36 - 86.87
Day's Volume 1,529
52-Week Range 33.08 - 87.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21.

GlobeNewsWire - 1 week ago

PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan...

GlobeNewsWire - 1 month ago

PITTSBURGH, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced t...

Business Wire - 1 month ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company”), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $100 million...

Business Wire - 1 month ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD,...

Business Wire - 3 months ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in non-invasive, redosable gene therapies, today announced that Krish S. Krishnan, chairman and chief ...

Business Wire - 3 months ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platf...

Business Wire - 4 months ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportu...

Business Wire - 4 months ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech, Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, inves...

Business Wire - 5 months ago

PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector ...

GlobeNewsWire - 5 months ago

PITTSBURGH, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simple...

GlobeNewsWire - 6 months ago

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection 

GlobeNewsWire - 6 months ago

The company is on track to file an IND for KB407 in 2021 The company is on track to file an IND for KB407 in 2021

GlobeNewsWire - 6 months ago

Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients

GlobeNewsWire - 7 months ago

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex...

GlobeNewsWire - 7 months ago

PITTSBURGH, July 28, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1...

GlobeNewsWire - 7 months ago

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1...

GlobeNewsWire - 9 months ago

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases...

GlobeNewsWire - 9 months ago

PITTSBURGH, May 18, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases...

GlobeNewsWire - 9 months ago

KB105 was well tolerated with no adverse events or immune response following redosing

GlobeNewsWire - 9 months ago

KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May...

Seeking Alpha - 10 months ago

Krystal Biotech: Revisiting This Gene Therapy Pioneer Ahead Of Q2 Data

GlobeNewsWire - 1 year ago

PITTSBURGH, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking o...

GlobeNewsWire - 1 year ago

PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Je...

Zacks Investment Research - 1 year ago

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

The Motley Fool - 1 year ago

Despite soaring already, these biotech stocks aren't finished climbing.

Other stocks mentioned: AXSM, KOD
Zacks Investment Research - 1 year ago

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors?

GlobeNewsWire - 1 year ago

PITTSBURGH, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for pat...

Seeking Alpha - 1 year ago

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be market disruptive.

Seeking Alpha - 1 year ago

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be market disruptive.

GlobeNewsWire - 1 year ago

PITTSBURGH, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the ...

GlobeNewsWire - 1 year ago

PITTSBURGH, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for pati...

The Motley Fool - 1 year ago

It was a great week for these three stocks, but can they continue climbing?

Other stocks mentioned: DOVA, MGTX
Benzinga - 1 year ago

Krystal Biotech Inc (NASDAQ: KRYS) announced positive Phase 2 data for KB103 Monday and said the gene therapy received the Regenerative Medicine Advanced Therapy designation from the FDA.

InvestorPlace - 1 year ago

In recent Krystal Biotech news, KRYS stock is soaring as the company's drug designed to treat a skin condition received expedited FDA review. The post Krystal Biotech News: Why Is KRYS Stock S...

Benzinga - 1 year ago

Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday.

Market Watch - 1 year ago

Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had received an expedited review designation from the FDA for its lead drug candidate...

InvestorPlace - 1 year ago

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing.

Other stocks mentioned: BMRN, DRNA, GBT, IOVA
Seeking Alpha - 1 year ago

Krystal Biotech Inc. is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017.

About KRYS

Krystal Biotech, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB4... [Read more...]

Industry
Biotechnology
IPO Date
Sep 20, 2017
CEO
Krish S. Krishnan
Employees
51
Stock Exchange
NASDAQ
Ticker Symbol
KRYS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is 95.10, which is an increase of 12.85% from the latest price.

Price Target
$95.10
(12.85% upside)
Analyst Consensus: Strong Buy